康泰生物
(300601)
| 流通市值：115.88亿 | | | 总市值：143.75亿 |
| 流通股本：9.00亿 | | | 总股本：11.17亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 1,840,837,989.25 | 1,273,006,190.84 | 631,111,744.14 | 2,673,083,107.93 |
| 营业总成本 | 1,736,185,760.91 | 1,194,441,307.03 | 599,367,752.11 | 2,504,875,738.79 |
| 其他经营收益 | | | | |
| 营业利润 | 80,726,255.2 | 46,581,668.34 | 40,636,356.48 | 38,069,305.12 |
| 利润总额 | 76,906,803 | 41,316,457.36 | 39,948,409.67 | 45,464,124.47 |
| 净利润 | 91,954,627.38 | 47,718,308.42 | 33,600,071.1 | 70,273,947.22 |
| 每股收益 | | | | |
| 其他综合收益 | -97,384.13 | -52,686.66 | -35,940.55 | -115,810.65 |
| 综合收益总额 | 91,857,243.25 | 47,665,621.76 | 33,564,130.55 | 70,158,136.57 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 6,210,628,178.72 | 6,205,486,162.6 | 5,956,587,525.96 | 5,994,731,385.56 |
| 非流动资产: | | | | |
| 非流动资产合计 | 7,710,070,513.18 | 7,727,045,334.37 | 8,029,828,631.35 | 8,100,687,031.3 |
| 资产总计 | 13,920,698,691.9 | 13,932,531,496.97 | 13,986,416,157.31 | 14,095,418,416.86 |
| 流动负债: | | | | |
| 流动负债合计 | 1,992,195,130.55 | 2,030,605,364.46 | 2,074,853,594.75 | 2,215,684,335.34 |
| 非流动负债: | | | | |
| 非流动负债合计 | 2,218,863,177.13 | 2,237,751,507.53 | 2,246,404,590.73 | 2,248,145,880.01 |
| 负债合计 | 4,211,058,307.68 | 4,268,356,871.99 | 4,321,258,185.48 | 4,463,830,215.35 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 9,687,941,995.89 | 9,642,997,493.23 | 9,665,052,013.2 | 9,631,743,291.33 |
| 股东权益合计 | 9,709,640,384.22 | 9,664,174,624.98 | 9,665,157,971.83 | 9,631,588,201.51 |
| 负债和股东权益合计 | 13,920,698,691.9 | 13,932,531,496.97 | 13,986,416,157.31 | 14,095,418,416.86 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,994,976,414.82 | 1,244,574,860.46 | 541,946,587.85 | 2,993,877,739.25 |
| 经营活动现金流出小计 | 1,743,257,832.21 | 1,219,870,911.17 | 641,222,486.18 | 2,358,308,453.89 |
| 经营活动产生的现金流量净额 | 251,718,582.61 | 24,703,949.29 | -99,275,898.33 | 635,569,285.36 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,573,184,418.07 | 1,434,075,354.97 | 636,751,308.45 | 4,398,711,211.98 |
| 投资活动现金流出小计 | 2,690,278,105.07 | 1,340,229,595.55 | 600,449,552.81 | 4,882,722,833.18 |
| 投资活动产生的现金流量净额 | -117,093,687 | 93,845,759.42 | 36,301,755.64 | -484,011,621.2 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 36,250,000 | 35,000,000 | 11,000,000 | 51,665,606.11 |
| 筹资活动现金流出小计 | 75,313,373.37 | 39,241,290.64 | 120,604.5 | 396,473,821.72 |
| 筹资活动产生的现金流量净额 | -39,063,373.37 | -4,241,290.64 | 10,879,395.5 | -344,808,215.61 |
| 汇率变动对现金及现金等价物的影响 | -2,626,481.9 | -1,888,707.34 | -1,325,405.62 | -959,185.16 |
| 现金及现金等价物净增加额 | 92,935,040.34 | 112,419,710.73 | -53,420,152.81 | -194,209,736.61 |
| 期末现金及现金等价物余额 | 314,794,558.18 | 334,279,228.57 | 168,439,365.03 | 221,859,517.84 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 112,419,710.73 | - | -194,209,736.61 |
最新报告期：2026-10-27| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 西南证券 | 杜向阳 | 0.11 | 0.20 | 0.24 | 2026-10-27 |
| 东海证券 | 杜永宏 | 0.15 | 0.19 | 0.23 | 2026-09-11 |
| 中信建投 | 汤然,刘若飞,贺菊颖 | 0.11 | 0.22 | 0.34 | 2026-09-06 |
| 华泰证券 | 代雯,张云逸 | 0.09 | 0.12 | 0.14 | 2026-08-23 |